Testing a new drug for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced or metastatic solid tumor that has come back or is not responding to standard treatments.
- Your overall physical condition is good (able to do daily activities with little help).
- Your expected survival is at least 3 months.
- You agree to use effective birth control during and for 3 months after treatment, and not to donate sperm or eggs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
This early-phase study (Phase 1) tests Hemay181, a new cancer medicine, in people with advanced solid tumors that have not been controlled by standard treatment. The goal is to see how the medicine works in the body and whether it can shrink or control tumors safely.
This early-stage study tests an investigational drug (MHB088C) in adults with advanced or metastatic solid cancers that have gotten worse or can’t be treated with standard options. It aims to see if the drug is safe and can shrink tumors or control the cancer.
This trial tests an experimental drug called MHB046C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
This trial tests a combination of two experimental drugs, MHB088C and MHB039A, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This Phase 1/2 trial tests MHB036C in people with advanced or metastatic solid cancers that have stopped responding to standard treatments (or no standard options exist). It is meant to see how the drug works and how safe it is in this group.
Hear when a new Advanced/Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.